21 – 30 of 341
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
(
- Contribution to journal › Article
-
Mark
Re : Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Salvage radiotherapy after radical prostatectomy : functional outcomes in the LAPPRO trial after 8-year follow-up
(
- Contribution to journal › Article
-
Mark
Quality of Life in Patients with High-grade Non–muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations : The EAU-RF NIMBUS Trial
(
- Contribution to journal › Article
-
Mark
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer : A subgroup analysis of the randomised clinical TITAN study
(
- Contribution to journal › Article
- 2022
-
Mark
Risk of hernia formation after radical prostatectomy : a comparison between open and robot-assisted laparoscopic radical prostatectomy within the prospectively controlled LAPPRO trial
(
- Contribution to journal › Article
-
Mark
Analytical performance of aPROMISE : automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting
(
- Contribution to journal › Article
-
Mark
Liproca Depot : A New Antiandrogen Treatment for Active Surveillance Patients
(
- Contribution to journal › Article
-
Mark
Increasing rates of urinary- and bloodstream infections following transrectal prostate biopsy in South Sweden
(
- Contribution to journal › Article
-
Mark
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
(
- Contribution to journal › Article